Dr. Lal Path Labs vs Metropolis: share price, P/E, ROE and financials compared
Dr. Lal Path Labs
Metropolis Healthcare
Dr. Lal Path Labs and Metropolis at a glance
Dr. Lal Path Labs and Metropolis are both listed in Healthcare. Dr. Lal Path Labs is the larger by market cap, at ₹32,941 Cr against ₹11,803 Cr for Metropolis (2.8 times as large). On valuation, Metropolis has the lower P/E (52.8× against 56.5×) and the lower price-to-book (7.17× against 11.99×). On returns and margins, Dr. Lal Path Labs has the higher ROCE (25.7% against 15.7%), the higher ROE (22.6% against 14.6%) and the higher operating margin (26.7% against 21.7%). Over three years, Dr. Lal Path Labs has faster 3-year profit growth (+28.3% against +10.0% a year), while Metropolis has faster 3-year sales growth (+12.7% against +11.1% a year). Dr. Lal Path Labs carries less debt for its equity, with a debt-to-equity of 0.08× against 0.16×.
Key metrics, side by side
| Metric | Dr. Lal Path LabsLALPATHLAB | MetropolisMETROPOLIS |
|---|---|---|
| Price (₹) | 1,970.00 | 568.75 |
| Market cap (₹ Cr) | 32,941 | 11,803 |
| P/E | 56.5× | 52.8× (the lower figure, shaded) |
| P/B | 11.99× | 7.17× (the lower figure, shaded) |
| Dividend yield, trailing | 0.81% (the higher figure, shaded) | 0.35% |
| ROE | 22.6% (the higher figure, shaded) | 14.6% |
| ROCE | 25.7% (the higher figure, shaded) | 15.7% |
| Operating margin (OPM) | 26.7% (the higher figure, shaded) | 21.7% |
| Net margin (NPM) | 19.2% (the higher figure, shaded) | 12.6% |
| Sales CAGR 3Y | +11.1% | +12.7% (the higher figure, shaded) |
| Profit CAGR 3Y | +28.3% (the higher figure, shaded) | +10.0% |
| Debt to equity | 0.08× (the lower figure, shaded) | 0.16× |
| Interest cover | 30.3× (the higher figure, shaded) | 11.6× |
| Net profit TTM (₹ Cr) | – | – |
| 1Y return | +24.7% (the higher figure, shaded) | +12.5% |
| Promoter holding | 52.93% | 47.82% |
Dr. Lal Path Labs vs Metropolis: common questions
Which is bigger, Dr. Lal Path Labs or Metropolis?
By market cap, Dr. Lal Path Labs is bigger at ₹32,941 Cr, against ₹11,803 Cr for Metropolis (prices as of 6 Nov 2026).
Which has a lower P/E ratio, Dr. Lal Path Labs or Metropolis?
Dr. Lal Path Labs trades at a P/E of 56.5× and Metropolis at 52.8×. Metropolis has the lower P/E. P/E is the share price divided by earnings per share; it varies a lot between industries and with growth, so it says little on its own.
Which has a higher ROE, Dr. Lal Path Labs or Metropolis?
Dr. Lal Path Labs reports a return on equity of 22.6% and Metropolis 14.6%. Dr. Lal Path Labs has the higher ROE. ROE is net profit as a share of shareholders’ equity.
Which is growing faster, Dr. Lal Path Labs or Metropolis?
Over the last three years: Sales grew +11.1% a year at Dr. Lal Path Labs and +12.7% at Metropolis, so Metropolis grew sales faster; profit grew +28.3% a year at Dr. Lal Path Labs and +10.0% at Metropolis, so Dr. Lal Path Labs grew profit faster. Past growth doesn’t predict future growth.